What is HC Wainwright’s Estimate for Insmed Q1 Earnings?

Insmed, Inc. (NASDAQ:INSM) – Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Insmed in a research note issued on Monday, February 23rd. HC Wainwright analyst A. Fein forecasts that the biopharmaceutical company will post earnings per share of ($1.08) for the quarter. HC Wainwright has a “Buy” rating and a $230.00 price target on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s Q2 2026 earnings at ($1.05) EPS, FY2028 earnings at $2.92 EPS and FY2029 earnings at $6.09 EPS.

Other equities analysts have also recently issued reports about the company. Guggenheim decreased their price target on Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Stifel Nicolaus set a $205.00 target price on shares of Insmed in a report on Thursday. Wolfe Research set a $167.00 target price on shares of Insmed and gave the stock an “outperform” rating in a research note on Thursday, December 18th. Wells Fargo & Company dropped their price target on shares of Insmed from $234.00 to $208.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Barclays initiated coverage on shares of Insmed in a report on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $207.86.

Insmed Trading Down 3.6%

NASDAQ INSM opened at $159.03 on Tuesday. Insmed has a 1-year low of $60.40 and a 1-year high of $212.75. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The stock has a 50-day moving average of $164.37 and a 200-day moving average of $164.24. The firm has a market cap of $34.28 billion, a PE ratio of -24.81 and a beta of 1.11.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. During the same quarter in the previous year, the company earned ($1.32) earnings per share. The business’s quarterly revenue was up 152.6% on a year-over-year basis.

Insider Activity at Insmed

In related news, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $150.97, for a total value of $1,615,228.03. Following the completion of the sale, the chief executive officer owned 301,185 shares of the company’s stock, valued at $45,469,899.45. The trade was a 3.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Roger Adsett sold 791 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $156.17, for a total value of $123,530.47. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares in the company, valued at $16,680,517.70. The trade was a 0.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 178,952 shares of company stock worth $30,222,170. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in INSM. State of New Jersey Common Pension Fund D raised its stake in Insmed by 8.5% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 64,097 shares of the biopharmaceutical company’s stock worth $6,451,000 after acquiring an additional 5,027 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of Insmed by 7.2% in the second quarter. Oppenheimer Asset Management Inc. now owns 21,374 shares of the biopharmaceutical company’s stock worth $2,151,000 after purchasing an additional 1,439 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Insmed by 12.5% in the second quarter. Envestnet Asset Management Inc. now owns 365,827 shares of the biopharmaceutical company’s stock worth $36,817,000 after purchasing an additional 40,520 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Insmed during the 2nd quarter valued at $22,574,000. Finally, Teacher Retirement System of Texas lifted its stake in shares of Insmed by 7.3% during the 2nd quarter. Teacher Retirement System of Texas now owns 49,013 shares of the biopharmaceutical company’s stock valued at $4,933,000 after buying an additional 3,330 shares in the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.